We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

60 hedge funds and large institutions have $163M invested in Foghorn Therapeutics in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

0.3% more ownership

Funds ownership: 62.43% → 62.73% (+0.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less capital invested

Capital invested by funds: $166M → $163M (-$3.72M)

8% less funds holding

Funds holding: 65 → 60 (-5)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

82% less call options, than puts

Call options by funds: $3K | Put options by funds: $17K

Holders
60
Holders Change
-5
Holders Change %
-7.69%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
18
Reduced
15
Closed
10
Calls
$3K
Puts
$17K
Net Calls
-$14K
Net Calls Change
-$485K

Top Buyers

1
RJA
Raymond James & Associates
Florida
+$3.49M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$856K
3
Citadel Advisors
Citadel Advisors
Florida
+$584K
4
Russell Investments Group
Russell Investments Group
United Kingdom
+$196K
5
AAA
Affinity Asset Advisors
New York
+$175K

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$1.36M
2
Millennium Management
Millennium Management
New York
-$955K
3
GW
GW & Wade
Massachusetts
-$688K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$670K
5
RWM
Rockwood Wealth Management
Pennsylvania
-$400K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$78.6M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$18.7M -$670K -102,382 -3%
AG
3
Artal Group
Luxembourg
$10.7M – – –
EC
4
Euclidean Capital
New York
$7.82M – – –
BlackRock
5
BlackRock
New York
$7.7M -$49.1K -7,508 -0.6%
RJA
6
Raymond James & Associates
Florida
$6.68M +$3.49M +533,123 +98%
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.34M +$26.7K +4,077 +0.4%
DM
8
Deerfield Management
New York
$4.82M – – –
AI
9
Alphabet Inc
California
$3.11M – – –
State Street
10
State Street
Massachusetts
$2.54M +$35.2K +5,375 +1%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.39M +$103K +15,759 +4%
DCM
12
Driehaus Capital Management
Illinois
$2.13M +$89.5K +13,669 +4%
BC
13
Birchview Capital
Vermont
$1.64M – – –
RWM
14
Rockwood Wealth Management
Pennsylvania
$1.33M -$400K -61,120 -22%
Northern Trust
15
Northern Trust
Illinois
$1.15M +$30.5K +4,662 +3%
Citadel Advisors
16
Citadel Advisors
Florida
$949K +$584K +89,291 +140%
AAA
17
Affinity Asset Advisors
New York
$848K +$175K +26,780 +24%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$811K +$856K +130,847 New
Morgan Stanley
19
Morgan Stanley
New York
$580K -$1.36M -207,999 -69%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$440K -$105 -16 -0%
Charles Schwab
21
Charles Schwab
California
$341K – – –
N
22
Nuveen
North Carolina
$332K -$3.16K -483 -0.9%
BBA
23
Baker Bros. Advisors
New York
$279K – – –
Millennium Management
24
Millennium Management
New York
$235K -$955K -145,882 -79%
Man Group
25
Man Group
United Kingdom
$211K -$104K -15,855 Closed
1
2 3

FHTX Hedge Fund Activity: Q1 2023 in Review

60 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2023, worth a combined $163M — down 2.2% from $166M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FHTX and 5 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 18 added.

The largest buyer was Raymond James & Associates, adding an estimated $3.49M. The largest seller was Morgan Stanley, cutting an estimated $1.36M.

  • 60 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2023, down from 65 in Q4 2022.
  • Funds reported $163M of Foghorn Therapeutics stock for Q1 2023, down 2.2% quarter-over-quarter.
  • 5 funds opened new Foghorn Therapeutics positions in Q1 2023 and 10 closed out, a net change of -5 holders.
  • The largest Foghorn Therapeutics buyer in Q1 2023 was Raymond James & Associates, an estimated $3.49M added.
  • The largest Foghorn Therapeutics seller in Q1 2023 was Morgan Stanley, an estimated $1.36M sold.

Based on aggregated 13F filings for Q1 2023.